MetaTarget Therapeutics, Inc.
Redefining targeted solid tumor treatment
Synthetic conjugate platform integrating:
Synthetic conjugate platform integrating:
- Accuracy of antibodies
- Penetration of peptides
- Increased tumor retention needed for maximum therapeutic impact
Founding Team
- Askar Kuchumov, Ph.D.15 years of hands-on entrepreneurial experience building innovative drug development companies starting as a VC investor.
Co-founder of several startups in oncology, having taken two programs from discovery stage to Phase II clinical. - Morten Meldal, Ph.D.2022 Nobel Laureate in Chemistry
Co-inventor of click chemistry’s copper-catalyzed azide–alkyne cycloaddition (CuAAC), a reaction that reshaped bioconjugation, diagnostics, and drug discovery.
He is a Professor at the University of Copenhagen, Denmark, and a pioneer of modern combinatorial and solid-phase peptide synthesis.
A New Class in Tumor-Targeted Therapy
Solid tumor treatment has reached a turning point.
Antibody-drug conjugates have proven that precision targeting works — but their size limits how deeply they can penetrate tumors, and their complexity drives high cost and safety trade-offs.
Peptide-drug conjugates can go deeper, yet lose impact by washing out too quickly.
Our answer is Tumor-Anchored ConjugatesTM — a proprietary, fully synthetic conjugate platform designed from the ground up to overcome these barriers. TACs unite three critical capabilities in one construct: the precision of antibodies, the penetration of peptides, and engineered tumor retention that keeps potent payloads active where they matter most.
Antibody-drug conjugates have proven that precision targeting works — but their size limits how deeply they can penetrate tumors, and their complexity drives high cost and safety trade-offs.
Peptide-drug conjugates can go deeper, yet lose impact by washing out too quickly.
Our answer is Tumor-Anchored ConjugatesTM — a proprietary, fully synthetic conjugate platform designed from the ground up to overcome these barriers. TACs unite three critical capabilities in one construct: the precision of antibodies, the penetration of peptides, and engineered tumor retention that keeps potent payloads active where they matter most.
The Unsolved Challenges in Solid Tumor Drug Delivery
- Antibody-Drug Conjugates (ADCs)Clinically validated, but large size limits penetration into solid tumors; complex and costly to manufacture; long circulation time leads to increased off-target toxicities.
- Peptide-Drug Conjugates (PDCs)Excellent penetration but short tumor dwell time; payload clears too quickly to achieve full therapeutic effect.
- Unmet NeedA delivery system with the precision of antibodies, the deep reach of peptides, and the anchoring power to stay in tumors long enough to maximize therapeutic impact - without antibody complexity.
Our Solution: Tumor-Anchored ConjugatesTM
TACs are built to rival ADCs in precision while surpassing them in penetration, safety, and scalability.
-
Engineered Anchoring MechanismKeeps the drug localized, increasing dwell time and therapeutic index. -
High-affinity / High-avidity bindingto tumor-associated or tumor microenvironment markers ensures high tumor specificity and increased retention time. -
Optional Conditional Activationwithin the tumor microenvironment using validated approaches for better safety profile. -
Built-in Dual Payload Delivery Mechanismvia target-dependent and target-independent pathways: broad range of targets / tumors / indications which can be accessed via TAC.
Why Now
- ADC Market Momentum$20B+ and growing; pharma is actively searching for alternatives with better penetration and lower cost.
- Advances in TechnologyAI/in silico cyclic peptide design now enables antibody-like affinity, enhanced stability with non-natural amino acids, and modular binders tailored to different tumor targets.
- Demand for Safer, More Potent PlatformsMarket pressure for higher therapeutic index, fewer side effects, and scalable and cost-effective manufacturing.
We are fundraising and building.
Let’s shape the future of tumor-targeted therapeutics - together.
Let’s shape the future of tumor-targeted therapeutics - together.
